Dialyse aktuell 2007; 11(6): 50-54
DOI: 10.1055/s-2007-986511
Markt und Forschung

© Georg Thieme Verlag KG Stuttgart · New York

Mehr als nur PTH-Senkung - Moderne Therapie des sekundären Hyperparathyreoidismus

Further Information

Publication History

Publication Date:
17 September 2007 (online)

Also available ateRef
 

Die Therapie des sekundären Hyperparathyreoidismus (sHPT) basiert heute im Wesentlichen auf drei Säulen: nichtselektive Vitamin-D-Rezeptor-Aktivatoren (nichtselektive VDRA: Calcitriol, Alfacalcidol, Doxercalciferol), selektive VDRA (sVDRA: Paricalcitol) und Kalzimimetika. Mit allen drei Präparategruppen kann eine Senkung des erhöhten Parathormons (PTH) erreicht werden. Das scheint für eine umfassende Behandlung der Erkrankung zwar ein wichtiges, jedoch nicht das einzige Kriterium zu sein. Auf dem ERA-EDTA-Kongress 2007 in Barcelona widmete sich ein hochkarätig, international besetztes Symposium dieser Thematik und lotete Vor- und Nachteile verschiedener Therapieansätze aus.

Literatur

  • 01 Agarwal R . Acharya M . Tian J . et al . Antiproteinuric effect of oral paricalcitol in chronic kidney disease.  Kidney Int. 2005;  68 2823-2828
    Search in Google Scholar
  • 02 Block GA . Martin KJ . de Francisco AL . et al . Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.  N Engl J Med. 2004;  350 1516-1525
    Search in Google Scholar
  • 03 Cardus A . Panizo S . Parisi E . et al . Differential effects of vitamin D analogs on vascular calcification.  J Bone Miner Res. 2007;  22 860-866
    Search in Google Scholar
  • 04 Holliday LS . Gluck SL . Slatopolsky E . Brown AJ . 1,25-Dihydroxy-19-nor-vitamin D(2), a vitamin D analog with reduced bone resorbing activity in vitro.  J Am Soc Nephrol. 2000;  11 1857-1864
    Search in Google Scholar
  • 05 Kalantar-Zadeh K . Kuwae N . Regidor DL . et a . Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.  Kidney Int. 2006;  70 771-780
    Search in Google Scholar
  • 06 Liu PT . Stenger S . Li H . et al . Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.  Science. 2006;  311 1770-1773
    Search in Google Scholar
  • 07 Lund R . et al . Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Nephrol Dial Transplant 2006; 21 (suppl 4): iv219-220. 
  • 08 Mizobuchi M . Morrissey J . Finch JL . et al . Combination therapy with an Angiotensin-converting enzyme inhibitor and a vitamin d analog suppresses the progression of renal insufficiency in uremic rats.  J Am Soc Nephrol. 2007;  18 1769-1806
    Search in Google Scholar
  • 09 Nakane M . Fey TA . Dixon DB . et al . Differential effects of Vitamin D analogs on bone formation and resorption.  J Steroid Biochem Mol Biol. 2006;  98 72-77
    Search in Google Scholar
  • 10 Noonan W . et al . Differential effects of VDRAs on aortic calcification as indexed by pulse wave velocity in uremic rats. Poster F-PO804, ASN 39th Renal Week Meeting, San Diego, USA, 2006. 
  • 11 Slatopolsky E . Cozzolino M . Finch JL . Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats.  Kidney Int. 2002;  62 1277-1284
    CrossrefSearch in Google Scholar
  • 12 Slatopolsky E . Cozzolino M . Lu Y . et al . Efficacy of 19-nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.  Kidney Int. 2003;  63 2020-2027
    CrossrefSearch in Google Scholar
  • 13 Slatopolsky E . Finch J . Ritter C . Takahashi F . Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.  Am J Kidney Dis. 1998;  32 40-47
    Search in Google Scholar
  • 14 Sprague SM . Lerma E . McCommick D . et al . .  . 2001;  38 (5 suppl 5) S51-S56
    Search in Google Scholar
  • 15 Sprague SM . Llach F . Amdahl M . et al . Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol.  Am J Kidney Dis. 2003;  63 1483-1490
    CrossrefSearch in Google Scholar
  • 16 Tan X . Li Y . Liu Y . et al . Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.  Kidney Int. 2006;  17 3382-3393
    CrossrefSearch in Google Scholar
  • 17 Teng M . Wolf M . Lowrie E . et al . Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.  N Engl J Med. 2003;  349 446-456
    CrossrefSearch in Google Scholar
  • 18 Thadhani R . et al . Paricalcitol and cardiac structure and function in animals and humans. Poster TH-FC094, ASN 39th Renal Week Meeting, San Diego, USA, 2006. 
  • 19 Wu-Wong JR . Melnick J . Vascular calcification in chronic kidney failure: role of vitamin D receptor.  Curr Opin Invest Drugs. 2007;  8 (3) 237-247
    Search in Google Scholar
  • 20 Wu-Wong JR . Nakane M . Ma J . et al . Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells.  Atherosclerosis. 2006;  186 20-28
    CrossrefSearch in Google Scholar
  • 21 Wu-Wong JR . Noonan W . Ma J . et al . Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification.  J Pharmacol Experim Therapeut. 2006;  318 90-98
    CrossrefSearch in Google Scholar
  • 22 Young EW . et al . Vitamin D therapy and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Poster TH-PO735, ASN 38th Renal Week Meeting, Philadelphia, USA, 2005. 

01 Dialysis Outcomes and Practice Patterns Study

02 Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering

03 Paricalcitol benefits in Renal failure Induced cardiac MOrbidity